A drug used in the treatment of Parkinson's disease.
| Member | Definition | Class |
|---|
| (S)-carbinoxamine maleate | The maleic acid salt of (S)-carbinoxamine. | (S)-carbinoxamine maleate |
| 2-bromoergocryptine mesylate | | bromocriptine methanesulfonate |
| a 77636 | An isochromene that is 3,4-dihydroisochromene-5,6-diol bearing additional aminomethyl and 1-adamantyl substituents at positions 1 and 3 respectively (the 1R,3S-diastereomer). Potent and selective dopamine D1-like receptor agonist (pEC50 values are 8.97 and < 5 for D1-like and D2-like receptors respectively). Displays anti-Parkinsonian activity following oral administration in vivo. | (1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol |
| a 77636 | A hydrochloride salt obtained by mixing equimolar amounts of (1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol with hydrochloric acid. Potent and selective dopamine D1-like receptor agonist (pEC50 values are 8.97 and < 5 for D1-like and D2-like receptors respectively). Displays anti-Parkinsonian activity following oral administration in vivo. | (1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol hydrochloride |
| amantadine | A member of the class of adamantanes that is used as an antiviral and antiparkinson drug. | amantadine |
| apomorphine | | apomorphine |
| benserazide | A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone. | benserazide |
| benserazide hydrochloride | A hydrochloride that is the monohydrochloride salt of benserazide. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide hydrochloride has no antiparkinson actions when given alone. | benserazide hydrochloride |
| biperiden | A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease. | biperiden |
| biperiden hydrochloride | The hydrochloride salt of biperiden. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease. | biperiden hydrochloride |
| bromocriptine | | bromocriptine |
| cabergoline | An N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia. | cabergoline |
| carbidopa | 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa. | carbidopa (anhydrous) |
| carbidopa | The hydrate of 3-(3,4-dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa. | carbidopa |
| carbinoxamine | An organochlorine compound that is 2-(4-chlorobenzyl)pyridine in which one of the benzylic hydrogens is substituted by 2-(dimethylamino)ethoxy group. It is an ethanolamine-type antihistamine, used as its maleate salt for treating hay fever, as well as mild cases of Parkinson's disease. | carbinoxamine |
| carbinoxamine maleate | The maleic acid salt of carbinoxamine. An ethanolamine-type antihistamine, used for treating hay fever, as well as mild cases of Parkinson's disease. | carbinoxamine maleate |
| cycrimine | A member of the class of piperidines that is 3-(piperidin-1-yl)propan-1-ol in which one of the hydrogen atoms at the 1-position is substituted by cyclopentyl, and the other is substituted by phenyl. A central anticholinergic, it is used as its hydrochloride salt in the management and treatment of Parkinson's disease. | cycrimine |
| diphenhydramine | An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug. | diphenhydramine |
| diphenhydramine hydrochloride | The hydrochloride salt of diphenhydramine. | diphenhydramine hydrochloride |
| entacapone | A monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group. | entacapone |
| levodopa | An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease | L-dopa zwitterion; L-dopa |
| lisuride | | lisuride |
| memantine | A primary aliphatic amine that is the 3,5-dimethyl derivative of 1-aminoadamantane. A low to moderate affinity uncompetitive (open-channel); NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. | memantine |
| memantine hydrochloride | A hydrochloride obtained by reaction of memantine with one equivalent of hydrochloric acid. A low to moderate affinity uncompetitive (open-channel); NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. | memantine hydrochloride |
| mesulergine | A member of the class of ergot alkaloids that is known to act on serotonin and dopamine receptors. | mesulergine |
| methixene | | metixene |
| minaprine | | minaprine |
| mk 458 | The hydrochloride salt of naxagolide. | naxagolide hydrochloride |
| naxagolide | An organic heterotricyclic compound that is (4aR,10bR)-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazine substituted by propyl and hydroxy groups at positions 4 and 9, respectively. It is a potent dopamine D2-receptor agonist and its hydrochloride salt was under clinical development by Merck & Co as a potential antiparkinsonian agent (now discontinued). | naxagolide |
| orphenadrine | A tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol. | orphenadrine |
| orphenadrine hydrochloride | A hydrochloride comprising equimolar amounts of ophenadrine and hydrogen chloride. | orphenadrine hydrochloride |
| pergolide | A diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction. | pergolide |
| pergolide mesylate | A methanesulfonate salt obtained from pergolide by mixing eqimolar amount of pergolide and methanesulfonic acid. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction. | pergolide mesylate |
| pramipexole | A member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively. | pramipexole |
| pridinol | A piperidine substituted at position 1 by a 3-hydroxy-3,3-diphenylpropyl group. | pridinol |
| procyclidine | A tertiary alcohol that consists of propan-1-ol substituted by a cyclohexyl and a phenyl group at position 1 and a pyrrolidin-1-yl group at position 3. | procyclidine |
| profenamine | A member of the class of phenothiazines that is phenothiazine in which the hydrogen attached to the nitrogen is substituted by a 2-(diethylamino)propyl group. An antimuscarinic, it is used as the hydrochloride for the symptomatic treatment of Parkinson's disease. | profenamine |
| profenamine hydrochloride | The monohydrochloride salt of profenamine. An antimuscarinic, it is used for the symptomatic treatment of Parkinson's disease. | profenamine hydrochloride |
| ropinirole | | ropinirole |
| selegiline hydrochloride, (r)-isomer | | selegiline hydrochloride |
| tolcapone | Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase. | tolcapone |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 24.6045 | 1 | 6 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 22.9702 | 1 | 3 |
| 67.9K protein | Vaccinia virus | Potency | 9.6375 | 2 | 3 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 18.5806 | 3 | 16 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 26.8354 | 1 | 11 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 3.5481 | 1 | 1 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 8.5389 | 1 | 3 |
| AR protein | Homo sapiens (human) | Potency | 22.9153 | 9 | 50 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 14.4019 | 2 | 8 |
| arylsulfatase A | Homo sapiens (human) | Potency | 16.7228 | 1 | 7 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 21.8439 | 2 | 4 |
| Ataxin-2 | Homo sapiens (human) | Potency | 24.9387 | 2 | 10 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 13.2615 | 2 | 10 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 19.5147 | 2 | 7 |
| atrial natriuretic peptide receptor 1 precursor | Homo sapiens (human) | Potency | 23.9341 | 1 | 1 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 63.6798 | 3 | 5 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 27.2928 | 1 | 2 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 48.5577 | 1 | 1 |
| caspase-3 | Homo sapiens (human) | Potency | 48.5577 | 1 | 1 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 27.4963 | 2 | 15 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 23.2909 | 2 | 6 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 16.3955 | 1 | 13 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 24.3616 | 1 | 2 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 23.5058 | 2 | 3 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 11.5957 | 2 | 7 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 44.8405 | 1 | 4 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 16.0782 | 1 | 7 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 17.8545 | 1 | 8 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 15.3625 | 1 | 10 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 11.5957 | 2 | 7 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 53.2154 | 2 | 15 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 19.2513 | 1 | 3 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 35.7168 | 1 | 2 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 11.9613 | 1 | 5 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 11.1712 | 1 | 13 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 10.4496 | 1 | 7 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 18.0528 | 2 | 16 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 10.3185 | 2 | 15 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 30.1074 | 1 | 7 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 1.0997 | 3 | 7 |
| D(1A) dopamine receptor | Sus scrofa (pig) | Potency | 23.2809 | 1 | 2 |
| D(3) dopamine receptor isoform e | Homo sapiens (human) | Potency | 15.8214 | 1 | 2 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 29.8554 | 1 | 1 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 40.4367 | 1 | 3 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 19.5957 | 2 | 2 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 32.1666 | 2 | 7 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 16.3682 | 1 | 7 |
| dopamine D1 receptor | Homo sapiens (human) | Potency | 2.8778 | 1 | 4 |
| endonuclease IV | Escherichia coli | Potency | 35.3358 | 1 | 3 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 25.6313 | 11 | 48 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 16.2332 | 2 | 6 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 28.4394 | 9 | 39 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 18.8470 | 1 | 27 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 28.0522 | 4 | 16 |
| eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 22.3872 | 1 | 1 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 19.5204 | 2 | 7 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 20.5511 | 3 | 8 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 33.5520 | 1 | 2 |
| G | Vesicular stomatitis virus | Potency | 11.9613 | 1 | 5 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 18.0528 | 1 | 8 |
| GALC protein | Homo sapiens (human) | Potency | 0.7079 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 18.0528 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 18.0528 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 18.0528 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 18.0528 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 18.0528 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 18.0528 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 18.0528 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 18.0528 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 18.0528 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 18.0528 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 18.0528 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 18.0528 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 18.0528 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 18.0528 | 1 | 8 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 18.0528 | 1 | 8 |
| geminin | Homo sapiens (human) | Potency | 11.1026 | 3 | 16 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 17.8491 | 2 | 25 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 28.1838 | 1 | 1 |
| GLS protein | Homo sapiens (human) | Potency | 21.4513 | 2 | 17 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 28.7968 | 1 | 2 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 22.3798 | 2 | 17 |
| glucokinase regulatory protein | Homo sapiens (human) | Potency | 5.0119 | 1 | 1 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 27.9818 | 1 | 3 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 56.2341 | 1 | 1 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 18.2974 | 2 | 3 |
| hexokinase-4 isoform 1 | Homo sapiens (human) | Potency | 5.0119 | 1 | 1 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 23.7713 | 2 | 12 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 37.6460 | 1 | 2 |
| histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 27.9349 | 2 | 3 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 54.0787 | 2 | 10 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 100.0000 | 1 | 1 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 11.9613 | 1 | 5 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 35.4813 | 1 | 2 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 14.1254 | 1 | 1 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 20.8907 | 2 | 4 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 6.9906 | 2 | 4 |
| IDH1 | Homo sapiens (human) | Potency | 3.3844 | 1 | 3 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 56.2341 | 2 | 3 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 11.9613 | 1 | 10 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 8.2082 | 2 | 4 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 28.3708 | 1 | 2 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 28.3708 | 1 | 2 |
| Interferon beta | Homo sapiens (human) | Potency | 16.6513 | 2 | 11 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 18.4680 | 2 | 15 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 25.1189 | 1 | 1 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 25.9234 | 2 | 8 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 6.5690 | 1 | 2 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 15.2123 | 1 | 6 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 17.1551 | 2 | 21 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 19.6191 | 2 | 10 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 6.9381 | 2 | 5 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 32.9473 | 2 | 3 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 10.4166 | 1 | 4 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 4.5640 | 2 | 4 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 25.1189 | 1 | 1 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 58.0479 | 1 | 1 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 18.5548 | 2 | 12 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 23.1093 | 1 | 1 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 30.1065 | 1 | 1 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 21.0251 | 2 | 6 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1 | 1 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 26.1369 | 3 | 20 |
| P53 | Homo sapiens (human) | Potency | 70.7946 | 1 | 1 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 100.0000 | 1 | 1 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 51.8270 | 2 | 4 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 14.9688 | 2 | 6 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 73.8118 | 1 | 5 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 13.6855 | 3 | 7 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 19.0259 | 3 | 9 |
| phosphoglycerate kinase | Trypanosoma brucei brucei TREU927 | Potency | 12.1739 | 3 | 3 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 53.5548 | 3 | 17 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 5.6234 | 1 | 1 |
| polyprotein | Zika virus | Potency | 33.5520 | 1 | 2 |
| polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 11.8259 | 1 | 3 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 15.8115 | 1 | 12 |
| PPM1D protein | Homo sapiens (human) | Potency | 20.5596 | 1 | 4 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 23.9911 | 3 | 17 |
| progesterone receptor | Homo sapiens (human) | Potency | 16.0506 | 3 | 6 |
| putative alpha-glucosidase | Oryza sativa Japonica Group (Japanese rice) | Potency | 28.1838 | 1 | 2 |
| pyruvate kinase | Leishmania mexicana mexicana | Potency | 25.1189 | 2 | 2 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 20.2522 | 2 | 14 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 58.0479 | 1 | 1 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 14.5610 | 1 | 11 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 27.0967 | 3 | 14 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 24.5339 | 3 | 9 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 18.9588 | 3 | 7 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 6.7016 | 1 | 1 |
| signal transducer and activator of transcription 6, interleukin-4 induced | Homo sapiens (human) | Potency | 100.0000 | 1 | 1 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 14.8672 | 2 | 7 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 14.8672 | 2 | 7 |
| Smad3 | Homo sapiens (human) | Potency | 0.1122 | 1 | 1 |
| snurportin-1 | Homo sapiens (human) | Potency | 56.2341 | 2 | 3 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 17.9560 | 1 | 7 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 4.9444 | 1 | 3 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 0.6310 | 1 | 1 |
| TDP1 protein | Homo sapiens (human) | Potency | 19.3857 | 2 | 42 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 4.1297 | 1 | 2 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 18.1676 | 3 | 23 |
| Thrombopoietin | Homo sapiens (human) | Potency | 11.7273 | 2 | 6 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 28.0459 | 2 | 40 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 2.5665 | 2 | 2 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 25.9487 | 5 | 10 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 24.3855 | 2 | 3 |
| transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | Potency | 19.9526 | 1 | 1 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 20.7491 | 1 | 1 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 5.6234 | 1 | 1 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 5.6234 | 1 | 1 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 50.6451 | 2 | 5 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 26.6482 | 2 | 11 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 1.9862 | 4 | 7 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 53.4417 | 1 | 10 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 27.9818 | 1 | 3 |
| WRN | Homo sapiens (human) | Potency | 5.4979 | 2 | 2 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | IC50 | 3.4010 | 3 | 6 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | Ki | 1.0282 | 6 | 9 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | Ki | 0.0040 | 1 | 3 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | IC50 | 3.4010 | 3 | 6 |
| 5-hydroxytryptamine receptor 1B | Homo sapiens (human) | Ki | 3.5080 | 1 | 1 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | Ki | 3.2530 | 2 | 4 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | IC50 | 6.7950 | 2 | 3 |
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 1E | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | IC50 | 6.7950 | 2 | 3 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | IC50 | 0.3568 | 1 | 5 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | IC50 | 6.7950 | 2 | 3 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 0.1050 | 2 | 6 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | Ki | 0.0030 | 2 | 2 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | IC50 | 0.7673 | 2 | 6 |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | IC50 | 6.7950 | 2 | 3 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | Ki | 0.4187 | 3 | 7 |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | Ki | 0.0030 | 2 | 2 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | IC50 | 0.4078 | 2 | 6 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | IC50 | 6.7950 | 2 | 3 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | Ki | 0.1605 | 4 | 8 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | Ki | 0.0022 | 11 | 11 |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | IC50 | 5.0968 | 3 | 4 |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | IC50 | 5.0968 | 3 | 4 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | IC50 | 0.4890 | 1 | 5 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | Ki | 0.2560 | 1 | 5 |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | IC50 | 5.4338 | 3 | 4 |
| 5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | IC50 | 6.7950 | 2 | 3 |
| 5-hydroxytryptamine receptor 5A | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | IC50 | 6.7950 | 2 | 3 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | IC50 | 0.2985 | 1 | 4 |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | IC50 | 6.7950 | 2 | 3 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | Ki | 1.5196 | 4 | 8 |
| 5-hydroxytryptamine receptor 7 | Cavia porcellus (domestic guinea pig) | IC50 | 20.2000 | 1 | 6 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | IC50 | 0.2050 | 2 | 2 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | Ki | 0.5980 | 2 | 2 |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | IC50 | 6.7950 | 2 | 3 |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | Ki | 0.1430 | 4 | 4 |
| Acetylcholinesterase | Electrophorus electricus (electric eel) | IC50 | 305.0000 | 2 | 2 |
| Acetylcholinesterase | Homo sapiens (human) | IC50 | 349.5650 | 8 | 9 |
| Acetylcholinesterase | Homo sapiens (human) | Ki | 3,492.5171 | 6 | 7 |
| Acetylcholinesterase | Bos taurus (cattle) | Ki | 173.2000 | 2 | 2 |
| Adenosine receptor A2a | Homo sapiens (human) | IC50 | 1.6250 | 1 | 2 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | IC50 | 3.1040 | 1 | 2 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | Ki | 3.0780 | 1 | 2 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 7.7500 | 1 | 1 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0019 | 2 | 2 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 7.7500 | 1 | 1 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0019 | 2 | 2 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | IC50 | 0.5280 | 1 | 3 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 7.7500 | 1 | 1 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | Ki | 0.2597 | 1 | 3 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0019 | 2 | 2 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | IC50 | 0.6088 | 1 | 4 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.2060 | 1 | 3 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | Ki | 0.1979 | 2 | 5 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 1.3000 | 1 | 2 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | IC50 | 0.4986 | 1 | 4 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.2060 | 1 | 3 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | Ki | 0.1956 | 2 | 5 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 1.3000 | 1 | 2 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | IC50 | 0.6448 | 1 | 3 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.2060 | 1 | 3 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | Ki | 0.0835 | 2 | 4 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 1.3000 | 1 | 2 |
| Alpha-ketoglutarate-dependent dioxygenase FTO | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
| Alpha-synuclein | Homo sapiens (human) | IC50 | 16.3000 | 1 | 2 |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | IC50 | 1.7000 | 1 | 1 |
| Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | IC50 | 0.9440 | 1 | 1 |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | IC50 | 0.0067 | 2 | 2 |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | IC50 | 0.0068 | 2 | 2 |
| Androgen receptor | Rattus norvegicus (Norway rat) | IC50 | 2.2810 | 1 | 1 |
| Androgen receptor | Rattus norvegicus (Norway rat) | Ki | 1.5210 | 1 | 1 |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | IC50 | 31.8590 | 1 | 1 |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | Ki | 26.1013 | 1 | 1 |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 | 118.4100 | 1 | 10 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | Ki | 3.3850 | 2 | 2 |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | Ki | 6.9350 | 2 | 2 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | IC50 | 1.4795 | 1 | 2 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | Ki | 0.8545 | 1 | 2 |
| Beta-2 adrenergic receptor | Homo sapiens (human) | IC50 | 0.0410 | 1 | 1 |
| Beta-2 adrenergic receptor | Homo sapiens (human) | Ki | 36.6763 | 3 | 3 |
| Beta-3 adrenergic receptor | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| Bile salt export pump | Homo sapiens (human) | IC50 | 270.2835 | 4 | 23 |
| Bile salt export pump | Rattus norvegicus (Norway rat) | IC50 | 47.2000 | 1 | 1 |
| Calcium release-activated calcium channel protein 1 | Homo sapiens (human) | IC50 | 500.0000 | 2 | 2 |
| Calcium/calmodulin-dependent protein kinase type II subunit alpha | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase type II subunit beta | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase type II subunit delta | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase type II subunit gamma | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| cAMP-dependent protein kinase catalytic subunit alpha | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| cAMP-dependent protein kinase catalytic subunit beta | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| cAMP-dependent protein kinase catalytic subunit gamma | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 9 |
| Carboxylic ester hydrolase | Equus caballus (horse) | Ki | 0.0200 | 1 | 1 |
| Catechol O-methyltransferase | Homo sapiens (human) | IC50 | 0.1150 | 4 | 5 |
| Catechol O-methyltransferase | Rattus norvegicus (Norway rat) | IC50 | 0.8706 | 3 | 4 |
| Cholinesterase | Equus caballus (horse) | IC50 | 4.1067 | 2 | 3 |
| Cholinesterase | Homo sapiens (human) | IC50 | 0.7033 | 3 | 3 |
| Cholinesterase | Homo sapiens (human) | Ki | 4,033.3467 | 3 | 3 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 | 25.6880 | 2 | 2 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 | 0.2053 | 1 | 3 |
| Cytochrome P450 2J2 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 | 2.4996 | 2 | 2 |
| D | Bos taurus (cattle) | IC50 | 0.2724 | 12 | 17 |
| D | Rattus norvegicus (Norway rat) | IC50 | 0.3214 | 13 | 18 |
| D | Bos taurus (cattle) | Ki | 10.0018 | 2 | 2 |
| D | Mus musculus (house mouse) | Ki | 0.1010 | 1 | 1 |
| D | Rattus norvegicus (Norway rat) | Ki | 9.3770 | 11 | 11 |
| D(1A) dopamine receptor | Homo sapiens (human) | IC50 | 0.9415 | 2 | 4 |
| D(1A) dopamine receptor | Homo sapiens (human) | Ki | 1.0998 | 12 | 17 |
| D(1A) dopamine receptor | Sus scrofa (pig) | Ki | 0.0039 | 1 | 1 |
| D(1B) dopamine receptor | Homo sapiens (human) | IC50 | 0.0250 | 1 | 1 |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0843 | 8 | 13 |
| D(1B) dopamine receptor | Homo sapiens (human) | Ki | 5.0075 | 2 | 2 |
| D(2) dopamine receptor | Bos taurus (cattle) | IC50 | 0.9606 | 13 | 19 |
| D(2) dopamine receptor | Homo sapiens (human) | IC50 | 1.6908 | 4 | 6 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0655 | 17 | 25 |
| D(2) dopamine receptor | Bos taurus (cattle) | Ki | 0.1019 | 2 | 2 |
| D(2) dopamine receptor | Homo sapiens (human) | Ki | 0.3533 | 49 | 63 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.4156 | 17 | 18 |
| D(3) dopamine receptor | Homo sapiens (human) | IC50 | 0.0078 | 2 | 4 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0843 | 8 | 13 |
| D(3) dopamine receptor | Homo sapiens (human) | Ki | 0.0109 | 27 | 36 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.0150 | 4 | 4 |
| D(4) dopamine receptor | Homo sapiens (human) | IC50 | 0.0250 | 1 | 1 |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0843 | 8 | 13 |
| D(4) dopamine receptor | Homo sapiens (human) | Ki | 0.0424 | 9 | 11 |
| Delta-type opioid receptor | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | IC50 | 1.4900 | 1 | 1 |
| E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | IC50 | 10.1367 | 3 | 3 |
| Endothelin receptor type B | Homo sapiens (human) | Ki | 0.0079 | 2 | 2 |
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | Ki | 0.0079 | 1 | 1 |
| Epidermal growth factor receptor | Homo sapiens (human) | IC50 | 451.4400 | 2 | 2 |
| estrogen receptor beta isoform 1 | Homo sapiens (human) | IC50 | 3.0540 | 1 | 1 |
| Genome polyprotein | Coxsackievirus B3 (strain Nancy) | IC50 | 2.4000 | 1 | 1 |
| Genome polyprotein | Dengue virus 2 Thailand/16681/84 | IC50 | 0.6400 | 5 | 5 |
| Genome polyprotein | Zika virus | IC50 | 17.3200 | 2 | 2 |
| Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | IC50 | 4.1375 | 11 | 11 |
| Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | Ki | 3.3800 | 3 | 6 |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | IC50 | 70.0724 | 13 | 19 |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | Ki | 0.7000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | IC50 | 3.4674 | 7 | 7 |
| Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | Ki | 3.8560 | 2 | 5 |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | IC50 | 73.8487 | 12 | 18 |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | Ki | 0.7000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | IC50 | 5.3100 | 4 | 4 |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | IC50 | 80.5624 | 11 | 16 |
| Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | Ki | 3.3800 | 3 | 6 |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | Ki | 0.7000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | IC50 | 85.7933 | 10 | 15 |
| Glutamate receptor ionotropic, NMDA 2C | Homo sapiens (human) | Ki | 3.8560 | 2 | 5 |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | Ki | 0.7000 | 1 | 2 |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | IC50 | 85.7933 | 10 | 15 |
| Glutamate receptor ionotropic, NMDA 2D | Homo sapiens (human) | Ki | 3.8560 | 2 | 5 |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | Ki | 0.7000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | IC50 | 85.7933 | 10 | 15 |
| Glutamate receptor ionotropic, NMDA 3A | Homo sapiens (human) | Ki | 3.8560 | 2 | 5 |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | Ki | 0.7000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | IC50 | 85.7933 | 10 | 15 |
| Glutamate receptor ionotropic, NMDA 3B | Homo sapiens (human) | Ki | 3.8560 | 2 | 5 |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | Ki | 0.7000 | 1 | 1 |
| Hexokinase-2 | Homo sapiens (human) | IC50 | 5.5200 | 1 | 1 |
| Histamine H1 receptor | Homo sapiens (human) | IC50 | 23.4157 | 2 | 5 |
| Histamine H1 receptor | Homo sapiens (human) | Ki | 0.0494 | 2 | 4 |
| Histamine H2 receptor | Homo sapiens (human) | IC50 | 4.0005 | 1 | 2 |
| Histamine H2 receptor | Homo sapiens (human) | Ki | 6.0884 | 3 | 4 |
| Histamine H3 receptor | Homo sapiens (human) | Ki | 0.0014 | 1 | 1 |
| Histamine H4 receptor | Homo sapiens (human) | Ki | 26.3290 | 2 | 2 |
| integrase, partial | Human immunodeficiency virus 1 | IC50 | 0.5939 | 2 | 2 |
| intestinal alkaline phosphatase precursor | Mus musculus (house mouse) | IC50 | 50.9000 | 1 | 1 |
| Krueppel-like factor 10 | Homo sapiens (human) | IC50 | 50.0000 | 2 | 2 |
| Large neutral amino acids transporter small subunit 1 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| lens epithelium-derived growth factor p75 | Homo sapiens (human) | IC50 | 0.5939 | 2 | 2 |
| Lysine-specific demethylase 4E | Homo sapiens (human) | Ki | 1.9800 | 1 | 1 |
| Matrix protein 2 | Influenza A virus (A/Puerto Rico/8/1934(H1N1)) | IC50 | 153.9250 | 4 | 4 |
| Matrix protein 2 | Influenza A virus (A/udorn/1972(H3N2)) | IC50 | 109.8600 | 5 | 5 |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | IC50 | 51.4000 | 2 | 2 |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 | 108.7500 | 1 | 10 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | IC50 | 0.2470 | 1 | 2 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | IC50 | 1.1600 | 1 | 2 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | Ki | 5.4243 | 4 | 5 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | IC50 | 0.7130 | 1 | 2 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | IC50 | 1.1600 | 1 | 2 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | Ki | 2.6302 | 3 | 4 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | IC50 | 0.4110 | 1 | 2 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | IC50 | 1.1600 | 1 | 2 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | Ki | 2.5450 | 3 | 4 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | IC50 | 0.2485 | 1 | 2 |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | IC50 | 1.1600 | 1 | 2 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | Ki | 0.0337 | 2 | 3 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | IC50 | 0.0950 | 1 | 2 |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | IC50 | 1.1600 | 1 | 2 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | Ki | 0.0680 | 1 | 2 |
| Neuronal acetylcholine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | IC50 | 6.0000 | 1 | 1 |
| Neuronal acetylcholine receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | IC50 | 6.0000 | 1 | 1 |
| Neuronal acetylcholine receptor subunit beta-4 | Rattus norvegicus (Norway rat) | IC50 | 6.0000 | 1 | 1 |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | IC50 | 31.8590 | 1 | 1 |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | Ki | 26.1013 | 1 | 1 |
| polyadenylate-binding protein 1 | Homo sapiens (human) | IC50 | 55.4900 | 2 | 2 |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | IC50 | 2.2580 | 1 | 1 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 | 15.1684 | 6 | 8 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | Ki | 26.1013 | 1 | 1 |
| Protein kinase C alpha type | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Protein kinase C beta type | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Protein kinase C delta type | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Protein kinase C epsilon type | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Protein kinase C eta type | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Protein kinase C gamma type | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Protein kinase C iota type | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Protein kinase C theta type | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Protein kinase C zeta type | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Protein orai-2 | Homo sapiens (human) | IC50 | 500.0000 | 2 | 2 |
| Protein orai-3 | Homo sapiens (human) | IC50 | 500.0000 | 2 | 2 |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | IC50 | 10.0000 | 1 | 2 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 | 1.2767 | 1 | 3 |
| Serine/threonine-protein kinase D1 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Serine/threonine-protein kinase D3 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | IC50 | 5.1925 | 1 | 2 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | Ki | 4.4460 | 1 | 1 |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | IC50 | 41.0000 | 1 | 1 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | IC50 | 3.1040 | 1 | 2 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | Ki | 3.0780 | 1 | 2 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | IC50 | 0.4580 | 1 | 1 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | Ki | 0.2430 | 1 | 1 |
| Solute carrier family 15 member 1 | Homo sapiens (human) | IC50 | 141,200.0000 | 1 | 1 |
| Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | IC50 | 220.0750 | 4 | 4 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | IC50 | 36.2120 | 3 | 5 |
| Solute carrier family 22 member 2 | Homo sapiens (human) | IC50 | 12.7500 | 2 | 2 |
| Solute carrier family 22 member 2 | Rattus norvegicus (Norway rat) | IC50 | 200.7250 | 4 | 4 |
| SUMO-conjugating enzyme UBC9 | Homo sapiens (human) | IC50 | 12.4200 | 2 | 2 |
| SUMO1 activating enzyme subunit 1 | Homo sapiens (human) | IC50 | 12.4200 | 2 | 2 |
| Tat | Human immunodeficiency virus 1 | IC50 | 8.8350 | 1 | 1 |
| Transthyretin | Homo sapiens (human) | IC50 | 16.6000 | 2 | 2 |
| Tryptophan 5-hydroxylase 1 | Rattus norvegicus (Norway rat) | IC50 | 0.2200 | 1 | 1 |
| Tyrosinase | Homo sapiens (human) | IC50 | 8,400.0000 | 1 | 1 |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | IC50 | 2.9385 | 1 | 2 |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | IC50 | 5.2620 | 1 | 2 |
| ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | IC50 | 20.0000 | 1 | 1 |
| Ubiquitin-like modifier activating enzyme 2 | Homo sapiens (human) | IC50 | 12.4200 | 2 | 2 |
| Vif | Human immunodeficiency virus 1 | IC50 | 1.4900 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Rattus norvegicus (Norway rat) | Ki | 1.0800 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Rattus norvegicus (Norway rat) | Ki | 1.0800 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Rattus norvegicus (Norway rat) | Ki | 1.0800 | 1 | 1 |